while in the speedily evolving area of oncology exploration, exact and economical mutation screening is important for creating qualified therapies. The KRAS solutions System plays a pivotal role On this landscape by giving thorough methods for KRAS mutation profiling and Evaluation. KRAS mutations, located in close to 95% of RAS-connected oncogenic